<DOC>
	<DOCNO>NCT01319825</DOCNO>
	<brief_summary>This open label pilot study determine whether milnacipran reduce headache frequency episodic chronic migraine sufferer .</brief_summary>
	<brief_title>Preventive Treatment Episodic Chronic Migraine</brief_title>
	<detailed_description>Patients episodic migraine and/or without aura chronic migraine treat 100 200 mg milnacipran total 4 month include one month titration phase 3 month maintenance phase . Baseline ( pre-treatment ) end-of-maintenance phase headache frequency record . There placebo treatment study . In addition headache frequency , parameter measure include safety tolerability .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Migraine Aura</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Migraine without aura chronic migraine . Subject age 18 70 . At least 2 migraine attack per month . Willing ang able give write informed consent . Willing able complete entire course study comply study instruction . Willing taper discontinue current preventive medication . Subject pregnant , lactate plan pregnancy next year . Subject female childbearing potential take adequate form birth control . Significant medical psychiatric disease abnormal laboratory data would preclude entry study . Previous failure four adequate trial preventive medication . Currently form antidepressant depression able discontinue . Currently demonstrate medication overuse headache . Currently uncontrolled narrow angle glaucoma . Currently take monoamine oxidase inhibitor . Subject history seizure . Participation investigational drug study within last 30 day 5 halflives , whichever longer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>